Peptides are 'natural' so they can't be FDA approved? Not quite

What's this video probably claiming?

Based on the caption, @pierre_vuala is making two connected arguments: first, that peptides are inherently safe or beneficial because they occur naturally in the human body, and second, that the FDA cannot approve naturally occurring substances because you cannot patent them. The creator's biology and kinesiology background is being used as a credibility signal. The hashtags suggest the video covers lip peptide treatments, but the category context points to a broader peptide therapy discussion likely touching on compounds like BPC-157, TB-500, or GHK-Cu. This is a familiar framing in the peptide community, and it contains a kernel of truth wrapped around some significant factual problems. The 'natural equals safe' logic and the patent-blocks-approval narrative both deserve direct scrutiny, because they are doing a lot of heavy lifting to make unregulated peptide use sound reasonable.

What does the science actually show?

The claim that natural origin prevents FDA approval is simply wrong. The FDA has approved numerous naturally occurring or endogenous substances. Insulin is a peptide. So is glucagon. Both are FDA-approved. Oxytocin is a naturally occurring peptide hormone and has been an FDA-approved drug since the 1960s. The patent argument conflates intellectual property law with regulatory approval, which are entirely separate processes. A manufacturer cannot patent the molecule itself but can patent a formulation, delivery method, or specific indication, which is exactly how branded peptide drugs have reached market. As for safety, the 'naturally occurring' framing ignores dose-response relationships entirely. BPC-157, for instance, is a synthetic 15-amino acid fragment derived from a gastric protein. Animal studies, including work by Sikiric et al. published in Current Pharmaceutical Design (2018), show tissue repair effects in rodents at doses around 10 mcg/kg, but there are no completed randomized controlled trials in humans. Natural origin tells you almost nothing about a compound's safety profile at pharmacological doses.

Where does the social media noise diverge from clinical reality?

The peptide space on TikTok and Instagram has developed a self-reinforcing information ecosystem where 'I did my research' often means reading other enthusiasts' threads rather than peer-reviewed literature. The compounds being discussed, BPC-157, TB-500, CJC-1295, ipamorelin, are largely in preclinical or very early clinical stages. CJC-1295 combined with ipamorelin has been studied as a growth hormone secretagogue stack, with research by Teichman et al. in the Journal of Clinical Endocrinology and Metabolism (2006) showing GH pulse amplification, but the long-term safety data in healthy adults simply does not exist at scale. MK-677, frequently marketed as a peptide, is technically a non-peptide GH secretagogue and was dropped by Merck after Phase 3 trials showed concerning signals including increased fasting glucose and edema. That detail rarely surfaces in creator content. The regulatory status matters too: most of these compounds are sold as 'research chemicals,' which means zero manufacturing oversight, variable purity, and no verified dosing consistency.

What should you actually know?

The FDA regulatory picture for peptides shifted significantly in 2023 and 2024. The FDA placed BPC-157 and TB-500 on a list of substances that cannot be compounded under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act, citing lack of clinical evidence of safety and effectiveness. This is not because they are naturally occurring and unpatentable. It is because the evidentiary bar for human use has not been cleared. GHK-Cu has more human skin data, primarily in cosmetic topical applications, but systemic peptide therapy claims go well beyond what that literature supports. Anyone considering peptide therapy should understand they are largely operating outside the boundaries of established evidence, with sourcing from unregulated suppliers, and without the safety net of FDA manufacturing standards. A biology background does not substitute for controlled clinical trial data, and enthusiasm for a compound category is not the same as evidence that specific compounds work safely in humans at the doses being circulated online.